Login to Your Account



Aveo Pharma's Tivozanib Trips on Overall Survival Data

By Catherine Shaffer
Staff Writer

Monday, August 6, 2012
In its second quarterly earnings report for 2012, Aveo Pharmaceuticals Inc., of Cambridge, Mass., said the FDA is concerned about overall survival trends in its ongoing TIVO-1 trial of tivozanib compared to sorafenib (Nexavar, Onyx Pharmaceuticals Inc.) in 517 patients with advanced renal cell carcinoma.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription